# The BMI Threshold Is Not Universal

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/the-bmi-threshold-is-not-universal

> Obesity is defined at BMI 30 in the US and at 25 in many Asian populations, because risk rises at lower body mass. Two phase 3 trials have now been run at those lower thresholds.

## Key points

- Many Asian populations define obesity at BMI ≥25, per WHO guidance, because risk rises at lower body mass.
- US labels and insurers require ≥30, or ≥27 with a complication. That ruler was calibrated elsewhere.
- STEP 11: −16.0% vs −3.1% at 44 weeks. OASIS 2 (oral 50 mg): −14.3% vs −1.3% at 68 weeks.
- STEP 1 is a different trial, with a different population, duration and placebo arm, so we do not compare the two.
- STEP 11 admitted from BMI 25 and enrolled a mean BMI of 31.3. The threshold widened eligibility, not the trial.

Obesity is defined at a BMI of 30 in the United States. In many Asian populations it is defined at **25**, consistent with World Health Organization guidance, because cardiometabolic risk rises at lower body mass.[1] Several phase 3 trials have now been run at lower thresholds: STEP 11 and STEP 12 for semaglutide, and [SURMOUNT-CN](https://glpwatchdog.org/research/trials/surmount-cn) for tirzepatide in China, which enrolled from a BMI of 28, or 24 with a weight-related condition.[1][6][7] The gap between where risk starts and where eligibility starts is a practical problem for patients. An earlier trial, [STEP 7](https://glpwatchdog.org/research/trials/step-7), asked whether semaglutide works as well in East Asian adults at all.

## Why the number differs

BMI is a ratio of weight to height, and it says nothing about what the weight is made of or where it sits. At the same BMI, people of South and East Asian descent tend on average to carry more visceral fat (the metabolically active kind around the organs) and less muscle than people of European descent.

The consequence is that type 2 diabetes, high blood pressure and cardiovascular disease appear at lower BMIs. A threshold calibrated on one population, applied to another, sets the line in the wrong place.

> **US eligibility rules encode one population’s threshold.** Section 1 of the Wegovy, Zepbound and Foundayo labels says obesity, or overweight with a weight-related condition, and prints no number.[3][4][5] The trials those labels describe enrolled at a BMI of 30, or 27 with a weight-related condition, and insurers generally write those figures into their rules. Someone of Asian descent whose metabolic risk profile matches a European-descent patient at BMI 32 can sit at 27 and be told they do not qualify, not because the risk is absent but because the ruler was calibrated elsewhere.

## What the two trials found

*Two of the phase 3 trials conducted in Asian populations. Each against its own placebo arm.*

|   | STEP 11[1] | OASIS 2[2] |
| --- | --- | --- |
| Where | South Korea and Thailand | Japan and South Korea |
| Drug | Semaglutide 2.4 mg weekly | **Oral** semaglutide 50 mg daily |
| Entry | BMI ≥ 25, no diabetes | BMI ≥ 27 with 2 complications, or ≥ 35 with 1 |
| Participants | 150 | 201 (25.4% with type 2 diabetes) |
| Duration | 44 weeks | 68 weeks |
| Weight change | −16.0% vs −3.1% | −14.3% vs −1.3% |
| Reached ≥5% | 96% vs 25% | 84.3% vs 17.2% |
| Stopped for adverse events | — | 4.5% |

In STEP 11, 78% reached a 10% reduction and 53% reached 15%, with waist circumference down 11.9 cm against 3.0 cm on placebo. Serious adverse events occurred in 13% on semaglutide against 8% on placebo. In OASIS 2, gastrointestinal effects hit 63.4% against 34.8%, yet only 4.5% on semaglutide stopped because of adverse events of any kind, a low figure for this class.[2]

## The comparison we are not going to make

> **STEP 11’s −16.0% is larger than the −14.9% everyone knows from STEP 1, and over a shorter period.** It would be easy to conclude that these drugs work better in Asian populations. That is a cross-trial comparison (different participants, countries, durations and placebo arms), and it is exactly the move this register criticizes when a seller makes it. We are not making it either.

What can be said without inventing anything: each trial beat its *own* placebo arm decisively, which is what a placebo-controlled trial is for. Whether response differs by ancestry is a question that requires a trial designed to ask it.

One detail complicates the threshold story. STEP 11 admitted people from a BMI of 25 upward, but the average BMI of those enrolled was **31.3**. The lower threshold widened who *could* enroll; it did not produce a trial conducted in people at BMI 25. What the drug does at the bottom of that range is less well characterized than the entry criterion suggests. STEP 12 narrows the gap. It enrolled only people below a BMI of 30 in mainland China and Taiwan, from 24 with a weight-related condition, and reported −12.1% on semaglutide against −2.2% on placebo at 44 weeks.[6]

## What follows from it

- **A BMI number is not self-interpreting.** The same figure carries different risk depending on ancestry, body composition and fat distribution.
- **Eligibility rules and clinical risk are different things.** Failing a BMI threshold is a statement about a rule, not about your metabolism.
- **Waist circumference is the cheap correction.** It reflects visceral fat directly, and it is the adiposity measure that tracked cardiovascular benefit in the largest analysis available (see [losing weight predicted more heart attacks](https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks)).
- **Oral dosing at 50 mg is a different drug from oral dosing at 7 or 14 mg**, so keep the dose in mind when comparing oral results (see [comparing trials that never met](https://glpwatchdog.org/research/comparing-trials-that-never-met)).

For the broader question of who needs treatment and why BMI is a poor instrument for deciding, see [beyond BMI](https://glpwatchdog.org/research/beyond-bmi-who-actually-needs-treatment).

## Frequently asked questions

### Why is obesity defined at BMI 25 in Asian populations?

Because cardiometabolic risk rises at lower body mass. At the same BMI, people of South and East Asian descent tend on average to carry more visceral fat and less muscle, so diabetes and cardiovascular disease appear earlier on the BMI scale. The lower threshold follows World Health Organization guidance.

### Does that affect who can get these drugs in the US?

It can. The current Wegovy, Zepbound and Foundayo labels say obesity, or overweight with a weight-related condition, without a number. Their trials enrolled at a BMI of 30, or 27 with a weight-related complication, and insurers generally require those figures. Those thresholds were calibrated on a different population. Someone whose metabolic risk would qualify a European-descent patient can sit below the line.

### Do these drugs work in Asian populations?

Both trials beat their own placebo arms decisively: 16.0% against 3.1% over 44 weeks in one, and 14.3% against 1.3% over 68 weeks in the other.

### Do they work better in Asian populations?

That cannot be answered by comparing these results to trials run elsewhere. Different participants, countries, durations and placebo arms make that a cross-trial comparison rather than a like-for-like one. It would need a trial designed to ask it.

### Were these trials actually conducted at BMI 25?

The entry threshold was 25 in one of them, but the average BMI of participants enrolled was 31.3. The threshold widened eligibility rather than producing a trial in people at the bottom of the range. A later trial, STEP 12, enrolled only people below 30, starting from 24 with a weight-related condition.

## References

1. Lim S, Buranapin S, Bao X, et al. Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. 2025. PMID: 40825340. https://pubmed.ncbi.nlm.nih.gov/40825340/
2. Kadowaki T, Heftdal LD, Ko HJ, et al. Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. JAMA Internal Medicine. 2025. PMID: 40758358. https://pubmed.ncbi.nlm.nih.gov/40758358/
3. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information (sections 1 and 14). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
4. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information (sections 1 and 14). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
5. Eli Lilly and Company FOUNDAYO (orforglipron) tablets: prescribing information (sections 1 and 14). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
6. Guo L, Bao X, Huang KC, et al. Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial. The Lancet Diabetes & Endocrinology. 2026. PMID: 42575111. https://pubmed.ncbi.nlm.nih.gov/42575111/
7. Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. PMID: 38819983. https://pubmed.ncbi.nlm.nih.gov/38819983/

---

Cite as: GLP Watchdog, Nora Bissett, "The BMI Threshold Is Not Universal", published 2026-08-20, updated 2026-11-01. https://glpwatchdog.org/research/the-bmi-threshold-is-not-universal

Canonical HTML page: https://glpwatchdog.org/research/the-bmi-threshold-is-not-universal

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
